(Q37872655)

24 August 2017

1 reference

title

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs (English)

1 reference

24 August 2017

Shin Ogita

1

1 reference

PubMed ID

21547565

24 August 2017

Patricia Lorusso

series ordinal

2

1 reference

24 August 2017

6 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

6

1 reference

24 August 2017

103-117

1 reference

24 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-011-0176-7

24 August 2017

0 references

cites work

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Mutation of the PIK3CA oncogene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Somatic mutation and gain of copy number of PIK3CA in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

PTEN1 is frequently mutated in primary endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Promoter methylation and silencing of PTEN in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Akt activation by growth factors is a multiple-step process: the role of the PH domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Absence of AKT1 mutations in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Complexity of the TOR signaling network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

TSC2: filling the GAP in the mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

The Rheb family of GTP-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

PDK1, the master regulator of AGC kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

The glamour and gloom of glycogen synthase kinase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Structure/function relationships underlying regulation of FOXO transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Emerging common themes in regulation of PIKKs and PI3Ks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

p110δ, a novel phosphoinositide 3-kinase in leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phase II study of perifosine in previously untreated patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A Phase 2 study of perifosine in advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A Phase II Trial of Tricyclic Nucleoside Phosphate in Patients with Advanced Squamous Cell Carcinoma of the Cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

OSU-03012 in the treatment of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Discovery of dibenzo[c,f][2,7]naphthyridines as potent and selective 3-phosphoinositide-dependent kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0176-7

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation

21 January 2018

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer

1 reference

12 December 2020

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

1 reference

12 December 2020

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

1 reference

12 December 2020

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

12 December 2020

In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin

1 reference

12 December 2020

Phase I study of tricyclic nucleoside phosphate

1 reference

12 December 2020

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

1 reference

12 December 2020

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer

1 reference

12 December 2020

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

1 reference

12 December 2020

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

1 reference

12 December 2020

Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.

1 reference

12 December 2020

Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features

1 reference

12 December 2020

Somatic mutations of PTEN in glioblastoma multiforme.

1 reference

12 December 2020

A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

1 reference

12 December 2020

Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition

1 reference

12 December 2020

Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells

1 reference

12 December 2020

PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma

1 reference

12 December 2020

10.1007/S11523-011-0176-7

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21547565